Mutant polypeptide and method for producing l-valine using same
By introducing variant polypeptides with specific amino acid substitutions into microorganisms, the L-valine production capacity is enhanced, addressing the low production challenges in existing methods, resulting in higher yields in strains like Corynebacterium glutamicum.
Patent Information
- Application Number
- PCT/KR2024/006708
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-28
AI Technical Summary
The industrial mass production of branched chain amino acids, such as L-valine, using microorganisms like Corynebacterium is challenging due to low production capacity and unclear genetic mechanisms.
Development of variant polypeptides with specific amino acid substitutions, particularly at positions 154 and 42, in acetohydroxy acid synthase subunits, which are introduced into microorganisms to enhance L-valine production, including Corynebacterium glutamicum, by modifying the polynucleotides encoding these polypeptides and expressing them in the microorganisms.
The modified microorganisms exhibit increased L-valine production capabilities, with strains like Corynebacterium glutamicum showing up to 23% higher yields compared to unmodified strains, indicating improved production efficiency.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
Mutant polypeptide and method for producing L-valine using the same
[0001] The present disclosure relates to a variant polypeptide; a polynucleotide encoding the variant polypeptide; a microorganism comprising the variant polypeptide or a polynucleotide encoding the variant polypeptide; a use for producing L-valine; a method for producing L-valine; and a method for increasing the L-valine production capacity of a microorganism.
[0002]
[0003] L-amino acids are the basic structural units of proteins and are used as important materials for pharmaceutical raw materials, food additives, animal feed, nutritional supplements, pesticides, and disinfectants. In particular, branched-chain amino acids (BCAAs) are a general term for the essential amino acids L-valine, L-leucine, and L-isoleucine. These branched-chain amino acids have antioxidant effects and promote protein synthesis in muscle cells.
[0004] The production of branched-chain amino acids using microorganisms is primarily accomplished by microorganisms of the genus Corynebacterium, which are known to biosynthesize 2-ketoisocaproic acid (2-Ketoisocaproate) from pyruvate as a precursor through several steps [Republic of Korea Patent Registration No. 10-0220018, Republic of Korea Patent Registration No. 10-0438146]. However, the production of branched-chain amino acids using these microorganisms presents a challenge: industrial mass production is difficult.
[0005]
[0006] The present disclosure relates to a variant polypeptide; a polynucleotide encoding the variant polypeptide; a microorganism comprising the variant polypeptide or a polynucleotide encoding the variant polypeptide; a use for producing L-valine; a method for producing L-valine; and a method for increasing the L-valine production capacity of a microorganism.
[0007]
[0008] One aspect of the present disclosure provides a variant polypeptide in which the amino acid corresponding to position 154 of SEQ ID NO: 1 is substituted with another amino acid.
[0009] In one specific example, the amino acid corresponding to position 154 of the above sequence number 1 may be substituted with an amino acid having a charged side chain (an electrically charged amino acid).
[0010] A variant polypeptide according to any one of the preceding specific examples, wherein the amino acid comprising the charged side chain may be arginine, histidine or glutamic acid.
[0011] In another specific example, the variant polypeptide may comprise any one of the amino acid sequences represented by the following general formulae 1 to 3.
[0012] [General Formula 1]
[0013] EPFGIRELIX
[0014] [General Formula 2]
[0015] PGKLRALLDVLEPFGIRELIX
[0016] [General Formula 3]
[0017] GINRITVVVDADELNIEQITKQLNKLIPVLKVVRLDEETTIARAIMLVKVSADSTNRPQIVDAANIFRARVVDVAPDSVVIESTGTPGKLRALLDVMEPFGIRELIX
[0018] In the above general formulas 1 to 3, X may be an amino acid including a charged side chain.
[0019] A variant polypeptide according to any one of the preceding specific examples, wherein X may be arginine, histidine or glutamic acid.
[0020] In another specific example, the variant polypeptide may additionally have the amino acid corresponding to position 42 in the amino acid sequence of SEQ ID NO: 1 replaced with another amino acid.
[0021] A variant polypeptide according to any one of the preceding specific examples, wherein the other amino acid may be valine.
[0022] A variant polypeptide according to any one of the preceding specific examples, wherein the variant polypeptide may comprise the amino acid sequence NLVSLVSV, LSVLVQDVDGIISRVSGMFTRRAFNLVSLVSV, or MANSDVTRHILSVLVQDVDGIISRVSGMFTRRAFNLVSLVSV.
[0023] In another specific example, the variant polypeptide may comprise an amino acid sequence having at least 70% identity and less than 100% identity with SEQ ID NO: 1.
[0024] In another specific example, the variant polypeptide may be a variant of an acetohydroxy acid synthase subunit.
[0025] In another specific example, the variant polypeptide may comprise the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10.
[0026] Another aspect of the present disclosure provides a polynucleotide encoding the variant polypeptide.
[0027] Another aspect of the present disclosure provides a microorganism comprising the variant polypeptide or a polynucleotide encoding the variant polypeptide.
[0028] In one specific example, the microorganism may have increased L-valine production capacity compared to a microorganism comprising the polypeptide of SEQ ID NO: 1 or a polynucleotide encoding the same.
[0029] A microorganism according to any one of the preceding specific examples, wherein the microorganism may be a microorganism of the genus Corynebacterium.
[0030] As a microorganism according to any one of the preceding specific examples, the microorganism of the genus Corynebacterium may be Corynebacterium glutamicum.
[0031] Another aspect of the present disclosure provides a method for producing L-valine, comprising the step of culturing the microorganism in a medium.
[0032] In one specific example, the method may further comprise a step of recovering L-valine from the cultured microorganism, a culture of the microorganism, a fermented product of the microorganism, or the culture medium.
[0033] Another aspect of the present disclosure provides a composition for producing L-valine, comprising: the variant polypeptide; a polynucleotide encoding the variant polypeptide; a vector comprising the polynucleotide; or a microorganism comprising the variant polypeptide, the polynucleotide encoding the variant polypeptide, or the vector comprising the polynucleotide; a culture of the microorganism; or a combination of two or more thereof.
[0034] Another aspect of the present disclosure provides a use of the variant polypeptide; or a microorganism comprising the variant polypeptide or a polynucleotide encoding the variant polypeptide; for producing L-valine.
[0035] Another aspect of the present disclosure provides a method for increasing the L-valine production capacity of a microorganism, comprising the step of modifying the microorganism to express the mutant polypeptide.
[0036]
[0037] When culturing a microorganism containing the mutant polypeptide of the present disclosure, high yield L-valine production is possible compared to a microorganism having an existing unmodified polypeptide.
[0038]
[0039] This is specifically explained as follows. Meanwhile, each description and embodiment disclosed in this disclosure can also be applied to each other description and embodiment. That is, all combinations of various elements disclosed in this disclosure fall within the scope of this disclosure. Furthermore, the scope of this disclosure is not limited by the specific descriptions described below. Furthermore, numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated into this specification in their entirety by reference to more clearly explain the level of the technical field to which this disclosure belongs and the contents of this disclosure.
[0040]
[0041] One aspect of the present disclosure provides a variant polypeptide in which the amino acid corresponding to position 154 of SEQ ID NO: 1 is substituted with another amino acid.
[0042]
[0043] As used herein, the term "variant" or "variant polypeptide" refers to a polypeptide that differs from the parent sequence of the polypeptide by conservative substitutions and / or modifications of one or more amino acids, but retains the functions or properties of the polypeptide. The variant polypeptide differs from the identified sequence by several amino acid substitutions, deletions, or additions. Such variant polypeptides can generally be identified by modifying one or more amino acids in the amino acid sequence of the polypeptide and evaluating the properties of the modified polypeptide. That is, the ability of the variant polypeptide may be increased, unchanged, or decreased compared to the native polypeptide. Additionally, some variant polypeptides may include variant polypeptides in which one or more portions, such as the N-terminal leader sequence or the transmembrane domain, are deleted. Other variant polypeptides may include variants in which portions are deleted from the N- and / or C-terminus of the mature protein. The term "variant polypeptide" may be used interchangeably with terms such as variant, modified, mutated protein, variant, and variant (in English, modification, modified protein, mutant, mutein, divergent, variant, etc.), and is not limited thereto as long as the term is used in the meaning of variant.
[0044] Additionally, the variant polypeptide may contain deletions or additions of amino acids that have minimal impact on the properties and secondary structure of the polypeptide. For example, the polypeptide may be conjugated to a signal (or leader) sequence at the N-terminus of the polypeptide that is involved in co-translational or post-translational protein transfer. The polypeptide may also be conjugated to other sequences or linkers to facilitate identification, purification, or synthesis of the polypeptide.
[0045]
[0046] For example, in the present disclosure, a variant polypeptide means a polypeptide comprising one or more amino acid substitutions in the amino acid sequence of a wild-type polypeptide; or a polypeptide comprising one or more amino acid substitutions in the amino acid sequence of a known polypeptide (parent sequence).
[0047]
[0048] As used herein, the term "wild type" refers to a naturally occurring polypeptide that does not have any artificial modifications. When the term "wild type" is used in relation to a polypeptide, it refers to a naturally occurring polypeptide that does not have any artificial modifications (such as substitutions, additions, or deletions) at one or more amino acid positions. Similarly, when the term "wild type" is used in relation to a polynucleotide, it refers to a naturally occurring polynucleotide that does not have any artificial modifications (such as substitutions, additions, or deletions) at one or more nucleotide positions. However, a polynucleotide encoding a wild type polypeptide is not limited to a naturally occurring polynucleotide, and also includes a sequence encoding any wild type polypeptide.
[0049]
[0050] In the present disclosure, the parent sequence or backbone refers to a reference sequence into which modifications are to be introduced for producing a variant polypeptide. That is, the parent sequence may be a starting sequence into which mutations such as substitutions, additions, and / or deletions are to be introduced. The parent sequence may be a naturally occurring or wild type, or a variant in which one or more substitutions, additions, or deletions have occurred in the natural or wild type, or may be an artificially synthesized sequence.
[0051] In the present disclosure, the polypeptide comprising the parent sequence may be a polypeptide having acetohydroxy acid synthase subunit activity or IlvN. For example, the sequence of the polypeptide having acetohydroxy acid synthase subunit activity in the present disclosure can be obtained from the NCBI's GenBank, a known database. For example, the polypeptide having acetohydroxy acid synthase subunit activity in the present disclosure may be, but is not limited to, a polypeptide derived from a microorganism of the genus Corynebacterium or a strain of Corynebacterium glutamicum.
[0052]
[0053] In the present disclosure, the term "acetohydroxy acid synthase" is the first enzyme in L-valine biosynthesis, also called acetolactate synthase. Acetohydroxy acid synthase can catalyze the decarboxylation of pyruvate and the condensation reaction with another pyruvate molecule to produce acetolactate, a precursor of valine, or catalyze the decarboxylation of pyruvate and the condensation reaction with 2-ketobutyrate to produce acetohydroxybutyrate, a precursor of isoleucine.
[0054] Acetohydroxy acid synthase is encoded by two genes, ilvB and ilvN. The ilvB gene encodes the acetohydroxy acid synthase large subunit, and the ilvN gene encodes the acetohydroxy acid synthase small subunit. The small subunit encoded by the ilvN gene is thought to be crucial for feedback inhibition.
[0055] The term "acetohydroxy acid synthase subunit" in the present disclosure is not particularly limited thereto, but may be an acetohydroxy acid synthase subunit encoded by the ilvN gene or an IlvN protein.
[0056]
[0057] For example, a polypeptide comprising a parent sequence of the present disclosure may include an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 70% homology or identity therewith, but is not limited thereto, as long as it has acetohydroxy acid synthase subunit activity. Specifically, even if a part of the amino acid sequence of SEQ ID NO: 1 is deleted or substituted, or another sequence is added to the amino acid sequence of SEQ ID NO: 1, as long as the protein exhibits an effect corresponding to the acetohydroxy acid synthase subunit activity, it may be included in the polypeptide comprising the parent sequence. Specifically, the polypeptide comprising the parent sequence may include SEQ ID NO: 1 or an amino acid sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 1. The above sequence number 1 can be obtained from the known database, NCBI's GenBank or KEGG (Kyoto Encyclopedia of Genes and Genomes). For example, the polypeptide containing the parent sequence may be derived from the genus Corynebacterium or Corynebacterium glutamicum, and more specifically, may be a polypeptide / protein containing the amino acid sequence described in sequence number 1, but is not limited thereto. In addition, it is obvious that an auxiliary protein having an amino acid sequence in which some of the sequences are deleted, modified, substituted or added is also included within the scope of the present disclosure, as long as it has such homology or identity and exhibits an effect corresponding to the protein.
[0058] Meanwhile, in the present disclosure, the expression "an amino acid corresponding to a specific position in a specific amino acid sequence is replaced with another amino acid" is interpreted to mean that the amino acid sequence is used as a reference sequence, and in this case, the parent sequence may have any structure unless otherwise defined. Examples of the parent sequence are as described above.
[0059] In the present disclosure, the term "reference sequence" refers to a sequence that serves as a reference for specifying the Nth position in a specific amino acid sequence. For example, when a specific amino acid sequence and a reference sequence are aligned through a sequence alignment known in the art, and each amino acid residue of the specific amino acid sequence is numbered based on the alignment with reference to the amino acid residue position of the reference sequence, the position of the amino acid corresponding to the Nth position of the reference sequence within the specific amino acid sequence can be determined.
[0060]
[0061] In addition, the sequence of a polynucleotide encoding a polypeptide including a parent sequence having the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 70% or more homology or identity therewith can be obtained, for example, based on codon information known in the art. For example, the polypeptide including the parent sequence may be encoded by a polynucleotide having or including a base sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology or identity with the sequence of SEQ ID NO: 2 or a base sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology or identity with the sequence of SEQ ID NO: 2, or consisting of or consisting essentially of the base sequence, but is not limited thereto. In addition, the base sequence of SEQ ID NO: 2 can be obtained from a known database, such as, but not limited to, NCBI's GenBank.
[0062] In the present disclosure, the polynucleotide (gene) including the base sequence of SEQ ID NO: 2 may be used interchangeably with a polynucleotide (gene) having the base sequence of SEQ ID NO: 2 and a polynucleotide (gene) consisting of the base sequence of SEQ ID NO: 2.
[0063]
[0064] The variant polypeptide of the present disclosure may be a variant polypeptide in which the amino acid corresponding to position 154 of SEQ ID NO: 1 is substituted with another amino acid.
[0065] In one embodiment, the variant polypeptide of the present disclosure may have, but is not limited to, a sequence identity of at least 70% and less than 100% with the amino acid sequence of SEQ ID NO: 1.
[0066] Specifically, the variant of the present disclosure may include an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more; and less than 100% homology or identity with the amino acid sequence set forth in SEQ ID NO: 1, wherein the amino acid at position 154 from the N-terminus of SEQ ID NO: 1 is substituted with another amino acid. In addition, it is obvious that a variant having an amino acid sequence in which some sequences are deleted, modified, substituted, conservatively substituted or added is also included within the scope of the present disclosure, as long as it has such homology or identity and exhibits an effect corresponding to the variant of the present disclosure.
[0067] In one embodiment, the variant polypeptide may be, but is not limited to, a variant of an acetohydroxy acid synthase subunit.
[0068]
[0069] The above "other amino acid" is not limited to an amino acid different from the amino acid prior to substitution. Furthermore, when the present disclosure states that "a specific amino acid has been substituted," it is self-evident that the amino acid has been substituted with an amino acid different from the amino acid prior to substitution, even if it is not specifically stated that it has been substituted with another amino acid.
[0070] Amino acids can generally be classified based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of their residues.
[0071] Examples of these classifications include positively charged (basic) amino acids such as arginine, lysine, and histidine; negatively charged (acidic) amino acids such as glutamic acid and aspartic acid; amino acids with nonpolar side chains (nonpolar amino acids) such as glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline; and amino acids with polar or hydrophilic side chains (polar amino acids) such as serine, threonine, cysteine, tyrosine, asparagine, and glutamine. As another example, amino acids with charged side chains (electrically charged amino acids) include arginine, lysine, histidine, glutamic acid, and aspartic acid; and amino acids with uncharged side chains (neutral amino acids) include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. As another example, phenylalanine, tryptophan, and tyrosine can be classified as aromatic amino acids. As another example, valine, leucine, and isoleucine can be classified as branched amino acids. As another example, the 20 amino acids can be classified by size into five groups: glycine, alanine, and serine; cysteine, proline, threonine, aspartic acid, and asparagine; valine, histidine, glutamic acid, and glutamine; isoleucine, leucine, methionine, lysine, and arginine; and phenylalanine, tryptophan, and tyrosine. However, this is not necessarily limited to these groups.
[0072] For example, if it is described that "the amino acid corresponding to position 154 in SEQ ID NO: 1 is replaced with another amino acid," it may mean, but is not limited to, a replacement with arginine, histidine, glutamic acid, valine, glycine, isoleucine, phenylalanine, aspartate, cysteine, asparagine, alanine, proline, serine, tyrosine, lysine, tryptophan, methionine, threonine, or leucine, excluding glutamine.
[0073]
[0074] Even if the present disclosure describes a "protein having an amino acid sequence described by a specific sequence number," it is obvious that a protein having an amino acid sequence in which some sequences are deleted, modified, substituted, conservatively substituted, or added may also be used in the present disclosure, as long as it has the same or corresponding activity as the protein consisting of the amino acid sequence of the corresponding sequence number. For example, if it has the same or corresponding activity as the mutant protein, it does not exclude sequence additions that do not alter the function of the protein before or after the amino acid sequence, mutations that may occur naturally, silent mutations thereof, or conservative substitutions, and it is obvious that even if it has such sequence additions or mutations, it falls within the scope of the present disclosure.
[0075] The "N-position" of the present disclosure may include the N-position and an amino acid position corresponding to the N-position. Specifically, it may include an amino acid position corresponding to any amino acid residue in a mature polypeptide disclosed in a specific amino acid sequence. The specific amino acid sequence may be the amino acid sequence of SEQ ID NO: 1.
[0076] As used herein, the term "corresponding to" refers to an amino acid residue at a position listed in a polypeptide, or an amino acid residue that is similar, identical, or homologous to the residue listed in the polypeptide. Identifying an amino acid at a corresponding position may be determining a specific amino acid in a sequence that references a particular sequence. As used herein, "corresponding region" generally refers to a similar or corresponding position in a related or reference protein.
[0077] For example, any amino acid sequence can be aligned with SEQ ID NO: 1, and based on this, each amino acid residue of the amino acid sequence can be numbered by referring to the numerical position of the amino acid residue corresponding to the amino acid residue in SEQ ID NO: 1. For example, a sequence alignment algorithm such as that described in the present disclosure can identify the position of an amino acid, or the position at which a modification such as a substitution, insertion, or deletion occurs, by comparing it to a query sequence (also referred to as a “reference sequence”).
[0078] For such alignment, for example, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453), the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000), Trends Genet. 16: 276-277) can be used, but is not limited thereto, and any sequence alignment program known in the art, pairwise sequence comparison algorithm, etc. can be appropriately used.
[0079]
[0080] In any one of the embodiments described above, the variant polypeptide of the present disclosure may be one in which the amino acid corresponding to position 154 of SEQ ID NO: 1 is substituted with an electrically charged amino acid, specifically, but not limited to, arginine, histidine, glutamic acid, lysine or aspartic acid.
[0081] In any one of the embodiments described above, the variant polypeptide of the present disclosure may be, but is not limited to, a polypeptide in which the amino acid corresponding to position 154 of SEQ ID NO: 1 is substituted with arginine, histidine, or glutamic acid.
[0082] For example, the variant polypeptide of the present disclosure may include an amino acid sequence in which the amino acid corresponding to position 154 in the amino acid sequence set forth in SEQ ID NO: 1, which is arginine, histidine or glutamic acid, is fixed and has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%; and less than 100% homology or identity with SEQ ID NO: 1. In addition, it is obvious that a variant polypeptide having an amino acid sequence in which a part of the sequence is deleted, modified, substituted, conservatively substituted or added is also included within the scope of the present disclosure, as long as it has such homology or identity and exhibits an effect corresponding to the variant polypeptide of the present disclosure.
[0083] Meanwhile, a person skilled in the art can identify the amino acid corresponding to the 154th position of the amino acid sequence of SEQ ID NO. 1 of the present disclosure in any amino acid sequence through sequence alignment known in the art, and even if not described separately in the present disclosure, when "an amino acid at a specific position in a specific sequence number" is described, it is self-evident that it includes "an amino acid at a corresponding position" in any amino acid sequence.
[0084]
[0085] In another specific example, the variant polypeptide may comprise any one of the amino acid sequences represented by the following general formulae 1 to 3.
[0086] [General Formula 1]
[0087] EPFGIRELIX
[0088] [General Formula 2]
[0089] PGKLRALLDVLEPFGIRELIX
[0090] [General Formula 3]
[0091] GINRITVVVDADELNIEQITKQLNKLIPVLKVVRLDEETTIARAIMLVKVSADSTNRPQIVDAANIFRARVVDVAPDSVVIESTGTPGKLRALLDVMEPFGIRELIX
[0092] In the above general formulas 1 to 3, X may be an amino acid including a charged side chain.
[0093] Specifically, in the general formulas 1 to 3, X may be an amino acid corresponding to the 154th position of the amino acid sequence of sequence number 1 of the present disclosure.
[0094] A variant polypeptide according to any one of the preceding specific examples, wherein X may be arginine, histidine or glutamic acid.
[0095] For example, the general formula 1 may be composed of sequence number 23, the general formula 2 may be composed of sequence number 24, and the general formula 3 may be composed of sequence number 25.
[0096]
[0097] In one specific example, the variant polypeptide of the present disclosure may be one in which the amino acid corresponding to position 154 of SEQ ID NO: 1 is substituted with another amino acid, and additionally, the amino acid corresponding to position 42 in the amino acid sequence of SEQ ID NO: 1 is substituted with another amino acid, but is not limited thereto.
[0098] In one embodiment, the variant polypeptide of the present disclosure may comprise an amino acid sequence in which one or two amino acids at positions corresponding to positions 42 and 154 from the N-terminus of SEQ ID NO: 1 are substituted with other amino acids.
[0099] In one embodiment, the variant polypeptide of the present disclosure may be, but is not limited to, a polypeptide in which the amino acid corresponding to position 42 of SEQ ID NO: 1 is substituted with valine.
[0100] In any one of the embodiments described above, the variant polypeptide of the present disclosure may be, but is not limited to, a polypeptide in which the amino acid corresponding to position 154 of SEQ ID NO: 1 is substituted with arginine, histidine, or glutamic acid, and the amino acid corresponding to position 42 is substituted with valine.
[0101] For example, the variant polypeptide of the present disclosure may include an amino acid sequence that has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 1; and less than 100% homology or identity with SEQ ID NO: 1, wherein arginine, histidine, or glutamic acid is the amino acid corresponding to position 154 in the amino acid sequence set forth in SEQ ID NO: 1; and valine is the amino acid corresponding to position 42 in the amino acid sequence set forth in SEQ ID NO: 1. In addition, it is obvious that a variant polypeptide having an amino acid sequence in which some of the sequences are deleted, modified, substituted, conservatively substituted, or added is also included within the scope of the present disclosure, as long as it has such homology or identity and exhibits an effect corresponding to that of the variant polypeptide of the present disclosure.
[0102]
[0103] A variant polypeptide according to any one of the preceding specific examples, wherein the variant polypeptide may comprise the amino acid sequence NLVSLVSV (SEQ ID NO: 26), LSVLVQDVDGIISRVSGMFTRRAFNLVSLVSV (SEQ ID NO: 27), or MANSDVTRHILSVLVQDVDGIISRVSGMFTRRAFNLVSLVSV (SEQ ID NO: 28).
[0104] Specifically, valine, an amino acid located at the C-terminus of the amino acid sequence of SEQ ID NO: 26 to SEQ ID NO: 28, may be an amino acid corresponding to the 42nd position of the amino acid sequence of SEQ ID NO: 1 of the present disclosure.
[0105]
[0106] In another specific example, the variant polypeptide may comprise the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10.
[0107] Specifically, the variant polypeptide of the present disclosure may have, comprise, consist of, or consist essentially of an amino acid sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity with SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10.
[0108] For example, if the amino acid sequence has sequence additions or deletions, naturally occurring mutations, silent mutations or conservative substitutions that do not alter the function of the variant of the present disclosure at the N-terminus, C-terminus and / or within the amino acid sequence.
[0109] As used herein, the term "conservative substitution" refers to the replacement of one amino acid with another amino acid having similar structural and / or chemical properties. Such amino acid substitutions may generally occur based on similarities in the polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. For example, positively charged (basic) amino acids include arginine, lysine, and histidine; negatively charged (acidic) amino acids include glutamic acid and aspartate; aromatic amino acids include phenylalanine, tryptophan, and tyrosine; and hydrophobic amino acids include alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, and tryptophan. Additionally, amino acids can be classified into those with electrically charged side chains and those with uncharged side chains. Charged side chain amino acids include aspartic acid, glutamic acid, lysine, arginine, and histidine. Uncharged side chain amino acids can be further classified into nonpolar amino acids or polar amino acids. Nonpolar amino acids include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, and proline. Polar amino acids include serine, threonine, cysteine, tyrosine, asparagine, and glutamine. Typically, conservative substitutions have little or no effect on the activity of the resulting polypeptide. Typically, conservative substitutions may have little or no effect on the activity of a protein or polypeptide.
[0110]
[0111] Another aspect of the present disclosure provides a polynucleotide encoding the variant polypeptide.
[0112] In the present disclosure, the term "polynucleotide" means a polymer of nucleotides in which nucleotide units (monomers) are covalently bonded to form a long chain, a DNA or RNA strand of a certain length or longer, and more specifically, a polynucleotide fragment encoding the variant.
[0113] A polynucleotide encoding a variant polypeptide of the present disclosure may include, without limitation, any polynucleotide sequence encoding a variant polypeptide of the present disclosure. For example, a polynucleotide encoding a variant polypeptide of the present disclosure may be, but is not limited to, a polynucleotide sequence encoding the amino acid sequence of a variant polypeptide of the present disclosure.
[0114] For example, it may comprise a nucleic acid sequence encoding an amino acid sequence set forth in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 10. As an example of the present disclosure, a polynucleotide of the present disclosure may have or comprise SEQ ID NO: 4 or SEQ ID NO: 6. Additionally, a polynucleotide of the present disclosure may consist of, or consist essentially of, SEQ ID NO: 4 or SEQ ID NO: 6.
[0115] The polynucleotide of the present disclosure may be modified in various ways in the coding region without altering the amino acid sequence of the variant of the present disclosure, taking into account codon degeneracy or preferred codons in the organism expressing the variant of the present disclosure. Therefore, it is apparent that the present disclosure may also include a polynucleotide that can be translated into a polypeptide comprising the amino acid sequence of the variant of the present disclosure, or a polypeptide having homology or identity therewith, due to codon degeneracy. For example, the polynucleotide of the present disclosure may be SEQ ID NO: 4 or SEQ ID NO: 6, or a degenerated sequence thereof.
[0116] For example, the polynucleotide of the present disclosure has a base sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity with the sequence of SEQ ID NO: 2; and less than 100% homology or identity, wherein the codon encoding glutamine, which is an amino acid corresponding to position 461 of SEQ ID NO: 2, is replaced with a codon encoding an amino acid other than glutamine, for example, arginine, histidine, or glutamic acid; Or, the codon encoding glutamine, which is an amino acid corresponding to position 461 of SEQ ID NO: 2, is replaced with a codon encoding an amino acid other than glutamine, such as arginine, histidine, or glutamic acid, and the codon encoding alanine, which is an amino acid corresponding to position 125 of SEQ ID NO: 2, is replaced with a codon encoding an amino acid other than alanine, such as valine; but is not limited thereto. In addition, if it is a polynucleotide sequence that has such homology or identity and encodes the amino acid sequence of the variant polypeptide of the present disclosure, it is obvious that a variant having a polynucleotide sequence in which some sequences are deleted, modified, substituted, conservatively substituted, or added is also included within the scope of the present disclosure.
[0117] As another example, the polynucleotide of the present disclosure may have or comprise a nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with SEQ ID NO: 4 or SEQ ID NO: 6, or may consist of or consist essentially of a nucleic acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and less than 100% homology or identity with SEQ ID NO: 4 or SEQ ID NO: 6, but is not limited thereto.
[0118] Additionally, the polynucleotide of the present disclosure may include, without limitation, a probe that can be prepared from a known genetic sequence, for example, a sequence that can hybridize under stringent conditions with a complementary sequence to all or part of the polynucleotide sequence of the present disclosure.
[0119] The above "stringent conditions" refer to conditions that allow specific hybridization between polynucleotides. These conditions are specifically described in the literature (see J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; FM Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, 9.50-9.51, 11.7-11.8). For example, conditions under which polynucleotides having high homology or identity hybridize with each other, polynucleotides having 60% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology or identity hybridize with each other, and polynucleotides having lower homology or identity do not hybridize with each other, or conditions under which washing conditions of typical southern hybridization are performed once, specifically twice or three times, at a salt concentration and temperature equivalent to 60°C, 1×SSC, 0.1% SDS, specifically 60°C, 0.1×SSC, 0.1% SDS, and more specifically 68°C, 0.1×SSC, 0.1% SDS.
[0120] Hybridization requires that two nucleic acids have complementary sequences, although mismatches between bases are possible depending on the stringency of hybridization. The term "complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenine is complementary to thymine, and cytosine is complementary to guanine. Accordingly, the polynucleotides of the present disclosure may also include isolated nucleic acid fragments that are complementary in their entirety, as well as substantially similar nucleic acid sequences.
[0121] Specifically, a polynucleotide having homology or identity with the polynucleotide of the present disclosure can be detected using hybridization conditions including a hybridization step at a Tm value of 55°C and using the conditions described above. In addition, the Tm value may be, but is not limited to, 60°C, 63°C, or 65°C, and can be appropriately adjusted by a person skilled in the art depending on the purpose.
[0122] The appropriate stringency for hybridizing the polynucleotides depends on the length and degree of complementarity of the polynucleotides, variables which are well known in the art (e.g., J. Sambrook et al., supra).
[0123] As used herein, the terms "homology" or "identity" refer to the degree of similarity between two given amino acid sequences or base sequences, which may be expressed as a percentage. The terms homology and identity are often used interchangeably.
[0124] Sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard alignment algorithms, and may be combined with default gap penalties established by the program being used. In practice, homologous or identical sequences can generally hybridize with all or part of the sequence under moderate or high stringency conditions. It should be appreciated that hybridization also includes hybridization with polynucleotides containing common codons or codons that take codon degeneracy into account.
[0125] Whether any two polynucleotide or polypeptide sequences are homologous, similar or identical can be determined using known computer algorithms such as the "FASTA" program using default parameters, for example as in Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444. Alternatively, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) can be determined using the GCG program package (Devereux, J., et al, Nucleic Acids Research 12: 387(1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO ETA / .](1988) SIAM J Applied Math 48: 1073). For example, homology, similarity, or identity can be determined using BLAST or ClustalW of the National Center for Biotechnology Information Database.
[0126] Homology, similarity, or identity of polynucleotides or polypeptides can be determined by comparing sequence information, for example, using a GAP computer program such as that of Needleman et al. (1970), J Mol Biol. 48:443, as disclosed, for example, in Smith and Waterman, Adv. Appl. Math (1981) 2:482. In brief, the GAP program can be defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). Default parameters for the GAP program include (1) a binary comparison matrix (containing values of 1 for identity and 0 for non-identity) and (2) a comparison matrix as disclosed by Gribskov et al. (1986) Nucl. Acids Res. 48:443, as disclosed by Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979). 14: 6745 weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10, a gap extension penalty of 0.5); and (3) no penalty for terminal gaps. Accordingly, the term "homology" or "identity" as used herein refers to the relevance between sequences.
[0127]
[0128] Another aspect of the present disclosure provides a vector comprising a polynucleotide of the present disclosure. The vector may be, but is not limited to, an expression vector for expressing the polynucleotide in a microorganism.
[0129] The term "vector" as used herein may include a DNA construct comprising a base sequence of a polynucleotide encoding a target polypeptide operably linked to a suitable expression control region (or expression control sequence) so as to enable expression of the target polypeptide in a suitable host. The expression control region may include a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and sequences regulating the termination of transcription and translation. After being transformed into a suitable microorganism, the vector may replicate or function independently of the host genome, or may be integrated into the genome itself.
[0130] The vector used in the present disclosure is not particularly limited, and any vector known in the art can be used. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A can be used as phage vectors or cosmid vectors, and pDZ series, pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, and pET series can be used as plasmid vectors. Specifically, pDZ, pDC, pDC24, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors can be used.
[0131] For example, a polynucleotide encoding a target polypeptide can be inserted into a chromosome via a vector for intracellular chromosomal insertion. The insertion of the polynucleotide into the chromosome can be achieved by any method known in the art, for example, homologous recombination, but is not limited thereto. A selection marker for confirming the chromosomal insertion can be additionally included. The selection marker is used to select cells transformed with the vector, i.e., to confirm the insertion of the target nucleic acid molecule. Markers that confer a selectable phenotype, such as drug resistance, nutrient requirement, cytotoxic agent resistance, or expression of a surface polypeptide, can be used. In an environment treated with a selective agent, only cells expressing the selection marker survive or exhibit other phenotypic traits, so that transformed cells can be selected.
[0132] As used herein, the term "transformation" refers to introducing a vector containing a polynucleotide encoding a target polypeptide into a microorganism or into a microorganism, such that the polypeptide encoded by the polynucleotide can be expressed in the microorganism. The transformed polynucleotide can be located either within the chromosome of the microorganism or outside the chromosome, as long as it can be expressed in the microorganism. Furthermore, the polynucleotide includes DNA and / or RNA encoding the target polypeptide. The polynucleotide can be introduced in any form as long as it can be introduced into the microorganism and expressed. For example, the polynucleotide can be introduced into the microorganism in the form of an expression cassette, which is a genetic construct containing all elements necessary for autonomous expression. The expression cassette can typically include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal, which are operably linked to the polynucleotide. The expression cassette can be in the form of a self-replicating expression vector. Additionally, the polynucleotide may be introduced into a microorganism in its own form and operably linked to a sequence required for expression in the microorganism, but is not limited thereto.
[0133] Additionally, the term "operably linked" as used herein means that the polynucleotide sequence is functionally linked to a promoter sequence that initiates and mediates transcription of the polynucleotide encoding the target variant of the present disclosure.
[0134]
[0135] Another aspect of the present disclosure provides a microorganism comprising the variant polypeptide or a polynucleotide encoding the variant polypeptide.
[0136] Specifically, the microorganism may comprise a variant polypeptide of the present disclosure, a polynucleotide encoding the variant polypeptide, or a vector comprising the polynucleotide.
[0137] In one specific example, the microorganism of the present disclosure may be a microorganism having L-valine production ability.
[0138] In the present disclosure, the term "L-valine" means an L-amino acid having the chemical formula (CH3)2CHCH(NH2)COOH, which is one of the essential amino acids and structurally corresponds to a branched-chain amino acid along with L-leucine and L-isoleucine.
[0139]
[0140] As used herein, the term "microorganism (or strain)" includes both wild-type microorganisms and microorganisms that have undergone genetic modification, either naturally or artificially. It may be a microorganism that has a specific mechanism weakened or strengthened due to reasons such as the insertion of an external gene or the strengthening or inactivation of an endogenous gene, and may be a microorganism that includes genetic modification for the production of a desired polypeptide, protein, or product. As used herein, "microorganism," "strain," "host," and "host cell" may be used interchangeably without limitation with the same meaning.
[0141] As used herein, the term "recombinant microorganism" refers to a microorganism that has been genetically modified to exhibit a different genotype and / or phenotype compared to a naturally occurring microorganism (e.g., when the genetic modification affects the coding base (nucleic acid) sequence of the microorganism), and may include all progeny or potential progeny of the microorganism. As used herein, the terms "recombinant microorganism," "genetically modified microorganism," "recombinant host cell," "recombinant cell," and "recombinant strain" may be used interchangeably. The recombinant microorganism may, for example, express a gene not found in its native (non-recombinant) form; may not express a gene expressed in its native form; or may express a native gene in a manner different from that in which it is expressed in its native form.
[0142] For example, the microorganism of the present disclosure may be, but is not limited to, a microorganism comprising any one or more of a variant polypeptide of the present disclosure, a polynucleotide of the present disclosure, and a vector comprising a polynucleotide of the present disclosure; a microorganism modified to express a variant polypeptide of the present disclosure or a polynucleotide of the present disclosure; a recombinant microorganism expressing a variant polypeptide of the present disclosure or a polynucleotide of the present disclosure; or a recombinant microorganism having the activity of a variant polypeptide of the present disclosure.
[0143] As used herein, the term "microorganism producing L-valine" refers to a prokaryotic or eukaryotic microbial strain capable of producing L-valine within the organism, and the microorganism may include not only a microorganism endogenously capable of producing L-valine, but also a microorganism that does not endogenously have L-valine production ability but is endowed with L-valine production ability. The L-valine production ability may be endowed or enhanced by species improvement.
[0144] In one embodiment, the microorganism of the present disclosure may be, but is not limited to, a microorganism that naturally has the ability to produce a variant polypeptide of the present disclosure or L-valine; or a microorganism that has been introduced into a parent strain that does not have the ability to produce a variant polypeptide of the present disclosure or L-valine by a variant of the present disclosure or a polynucleotide encoding the same (or a vector comprising the polynucleotide) and / or has been given the ability to produce L-valine.
[0145] In one embodiment, the microorganism of the present disclosure includes, but is not limited to, a microorganism in which a chromosomal gene encoding a variant polypeptide of the present disclosure is mutated to comprise a variant polypeptide sequence of the present disclosure and / or a microorganism comprising a variant polypeptide of the present disclosure by introducing a vector comprising a polynucleotide encoding a variant polypeptide of the present disclosure.
[0146] As used herein, the term "unmodified microorganism (strain)" does not exclude a microorganism (strain) that contains a mutation that may occur naturally in a microorganism, and may refer to a wild-type microorganism (strain) or a natural microorganism (strain) itself, or a microorganism (strain) before its phenotype is changed by a genetic mutation caused by natural or artificial factors. As used herein, the term "unmodified microorganism (strain)" may be used interchangeably with "pre-modified microorganism (strain)", "unmodified microorganism (strain)", "parent microorganism", "parent strain", "wild-type microorganism (strain)", "reference microorganism (strain)", or "reference microorganism (strain)". As used herein, an unmodified microorganism may refer to a microorganism (strain) into which a variant polypeptide of the present disclosure is not introduced or before it is introduced; or a microorganism (strain) containing a wild-type polypeptide, but is not limited thereto. Additionally, in the present disclosure, the non-modified microorganism may be, but is not limited to, a microorganism comprising a polypeptide consisting of SEQ ID NO: 1 or a polynucleotide consisting of SEQ ID NO: 2.
[0147]
[0148] For example, the microorganism of the present disclosure includes, but is not limited to, a microorganism in which a gene on a chromosome encoding a polypeptide comprising a parent sequence of the present disclosure is mutated to include a variant polypeptide sequence of the present disclosure; and / or a microorganism in which a vector comprising a polynucleotide encoding a variant polypeptide of the present disclosure is introduced to include a variant polypeptide of the present disclosure.
[0149] For the purposes of the present disclosure, the microorganism of the present disclosure may include any microorganism capable of producing the desired L-valine, including the variant polypeptide of the present disclosure. For example, the microorganism of the present disclosure may be a microorganism having increased L-valine production ability by being transformed with a vector comprising a polynucleotide encoding the variant polypeptide of the present disclosure, thereby expressing the variant polypeptide of the present disclosure, but is not limited thereto. For another example, the microorganism of the present disclosure may be a microorganism having increased L-valine production ability by being introduced into a natural wild-type microorganism or a microorganism that produces L-valine with a polynucleotide encoding the variant polypeptide of the present disclosure, thereby expressing the variant polypeptide of the present disclosure. The microorganism with increased L-valine production ability may be a genetically engineered microorganism or a recombinant microorganism, and the microorganism with increased L-valine production ability may be a microorganism with increased L-valine production ability compared to a natural wild-type microorganism or an unmodified microorganism (e.g., a microorganism expressing a wild-type polypeptide or a polypeptide including a parent sequence; or a microorganism that does not express a variant polypeptide of the present disclosure), but is not limited thereto.
[0150] For example, the microorganism having the ability to produce L-valine of the present disclosure may include any microorganism that is transformed via a vector to express the variant polypeptide of the present disclosure and produce L-valine.
[0151] The microorganism of the present disclosure may include any microorganism capable of expressing the variant polypeptide of the present disclosure by various known methods in addition to introducing the polynucleotide or vector.
[0152]
[0153] For example, the microorganism with increased L-valine productivity of the present disclosure may be a microorganism with increased L-valine productivity compared to a parent microorganism (parent strain) before mutation or an unmodified microorganism (e.g., a microorganism expressing a wild-type polypeptide, a polypeptide including a parent sequence; or a polypeptide of SEQ ID NO: 1; a microorganism that does not express a mutant polypeptide of the present disclosure);; but is not limited thereto. For example, the unmodified microorganism, which is a target strain for comparing whether the L-valine productivity is increased, may be, but is not limited to, the KCCM11201P strain (US 8465962 B), the CJ7V strain (US 11180784 B2), or the CJ8V strain (US 11180784 B2).
[0154] For example, the microorganism having increased L-valine production ability of the present disclosure may be a microorganism having increased L-valine production ability compared to a microorganism comprising the polypeptide of SEQ ID NO: 1 or a polynucleotide encoding the same.
[0155] As another example, the microorganism with increased L-valine production ability of the present disclosure may be a microorganism with an L-valine production ability that is increased to an equivalent or greater degree compared to a microorganism comprising a polypeptide in which the amino acid corresponding to position 42 of SEQ ID NO: 1 is substituted with valine or a polynucleotide encoding the same.
[0156]
[0157] For example, the microorganism with increased L-valine production ability has an L-valine production ability of about 1% or more, specifically, about 1% or more, about 2% or more, about 3% or more, about 5% or more, about 10% or more, about 15% or more, about 16% or more, about 17% or more, about 18% or more, about 19% or more, about 20% or more, about 21% or more, about 22% or more, or about 23% or more (the upper limit is not particularly limited, and for example, about 200% or less, about 150% or less, about 100% or less, about 90% or less, about 80% or less, about 70% or less, about 65% or less, about 60% or less, about 55% or less, about 50% or less, about 45% or less, about 40% or less, or about 35% It may be increased by about 30% or less, or about 25% or less), but is not limited thereto, as long as it has a positive increase compared to the productivity of the parent strain or unmodified microorganism before the mutation. In another example, the recombinant strain with increased L-valine production ability may have an L-valine production ability increased by about 1.01 times or more, about 1.02 times or more, about 1.03 times or more, about 1.05 times or more, about 1.1 times or more, about 1.15 times or more, about 1.16 times or more, about 1.17 times or more, about 1.18 times or more, about 1.19 times or more, about 1.20 times or more, about 1.21 times or more, about 1.22 times or more, or about 1.23 times or more (the upper limit is not particularly limited, and may be, for example, about 10 times or less, about 5 times or less, about 3 times or less, about 2 times or less, about 1.5 times or less, or about 1.3 times or less), compared to the parent strain before mutation or the unmodified microorganism, but is not limited thereto. The term "about" above includes, but is not limited to, a range including ±0.5, ±0.4, ±0.3, ±0.2, ±0.1, etc., and includes all numerical values in a range equal to or similar to the numerical value following the term "about."
[0158]
[0159] As a microorganism according to any one of the preceding specific examples, the microorganism of the present disclosure may be a microorganism belonging to the genus Corynebacteria sp., Escherichia sp., Erwinia sp., Serratia sp., Providencia sp., Pseudomonas sp., Leptospira sp., Salmonella sp., Brevibacteria sp., Hypomononas sp., Chromobacterium sp., and Norcardia sp., or a microorganism belonging to the genus fungi or yeast, specifically, a microorganism belonging to the genus Corynebacterium, but is not limited thereto.
[0160] As an example of the present disclosure, the microorganism of the present disclosure is Corynebacterium glutamicum, Corynebacterium crudilactis, Corynebacterium deserti, Corynebacterium efficiens, Corynebacterium callunae, Corynebacterium stationis, Corynebacterium singulare, Corynebacterium halotolerans, Corynebacterium striatum, Corynebacterium ammoniagenes, Corynebacterium It may be Corynebacterium pollutisoli, Corynebacterium imitans, Corynebacterium testudinoris, or Corynebacterium flavescens. Specifically, the microorganism of the present disclosure may be a microorganism of the genus Corynebacterium, more specifically, but not limited to, Corynebacterium glutamicum.
[0161]
[0162] Meanwhile, the microorganism having L-valine production ability of the present disclosure includes all of a natural wild-type microorganism itself, a microorganism having improved L-valine production ability by strengthening or weakening a gene related to the L-valine production mechanism, or a microorganism having improved L-valine production ability by introducing or strengthening an external gene.
[0163] Meanwhile, it has already been known that microorganisms of the genus Corynebacterium can produce L-valine, but their production ability is significantly low, and neither the genes nor the mechanism acting on the production mechanism have been fully elucidated. Therefore, the Corynebacterium microorganism having L-valine production ability of the present disclosure may include a natural wild-type microorganism itself, a Corynebacterium microorganism having enhanced L-valine production ability by increasing or decreasing the expression of a gene related to the L-valine production mechanism, or a Corynebacterium microorganism having enhanced L-valine production ability by introducing or increasing the expression of an external gene.
[0164]
[0165] In the present disclosure, the term "introduction" refers to a method of delivering a polynucleotide encoding the acetohydroxy acid synthase variant or a vector containing the same to a host cell. Such introduction can be easily performed according to a method commonly known in the art. Common methods include the CaCl2 precipitation method, the Hanahan method which increases efficiency by using a reducing agent called dimethyl sulfoxide (DMSO) in the CaCl2 method, electroporation, calcium phosphate precipitation, protoplast fusion, a stirring method using silicon carbide fibers, a transformation method using PEG, dextran sulfate, lipofectamine, and desiccation / inhibition-mediated transformation methods. The method for transforming the vector is not limited to the above examples, and any transformation or transfection method commonly used in the art can be used without limitation. In addition, the delivered polynucleotide can be integrated and located within the chromosome of the host cell or located extrachromosomally, as long as it can be expressed in the host cell. In addition, the polynucleotide may be introduced in any form as long as it can be introduced into a host cell and expressed. For example, the polynucleotide may be introduced into a host cell in the form of an expression cassette, which is a polynucleotide structure that includes all elements necessary for self-expression, but is not limited thereto. The expression cassette typically includes a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal that are operably linked to the open reading frame (hereinafter abbreviated as "ORF") of the gene. The expression cassette may be in the form of an expression vector capable of self-replication. In addition, the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence necessary for expression in the host cell, but is not particularly limited thereto.
[0166]
[0167] Another aspect of the present disclosure provides a method for producing L-valine, comprising the step of culturing a microorganism of the present disclosure in a medium.
[0168] Specifically, the method for producing L-valine of the present disclosure may include, but is not limited to, a step of culturing a microorganism comprising a variant of the present disclosure, a polynucleotide of the present disclosure, or a vector of the present disclosure in a medium.
[0169] In this disclosure, the term "cultivation" refers to growing the microorganisms of this disclosure under appropriately controlled environmental conditions. The culturing process of this disclosure can be performed using appropriate media and culture conditions known in the art. Such culturing process can be easily adjusted and used by those skilled in the art depending on the selected strain. Specifically, the culturing process may be batch, continuous, and / or fed-batch, but is not limited thereto.
[0170] In the present disclosure, the term "medium" refers to a material containing nutrients as a main component necessary for culturing the microorganism of the present disclosure, and supplies nutrients and growth factors, including water essential for survival and growth. Specifically, the medium and other culture conditions used for culturing the microorganism of the present disclosure may be any medium used for culturing general microorganisms without particular limitation, but the microorganism of the present disclosure may be cultured under aerobic conditions in a general medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compound, amino acid, and / or vitamin, while controlling temperature, pH, etc. For example, a culture medium for a strain of the genus Corynebacterium can be found in the literature ["Manual of Methods for General Bacteriology" by the American Society for Bacteriology (Washington DC, USA, 1981)].
[0171] In the present disclosure, the carbon source may include carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc.; sugar alcohols such as mannitol, sorbitol, etc., organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc.; glycerol, propanediol, etc. In addition, natural organic nutrients such as starch hydrolysate, molasses, blackstrap molasses, rice winter, cassava, sugarcane bagasse, and corn steep liquor may be used, and specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted to reducing sugar) may be used, and other appropriate amounts of carbon sources may be used in various ways without limitation. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.
[0172] The nitrogen source may include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc.; organic nitrogen sources such as amino acids such as glutamic acid, methionine, glutamine, etc.; peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolysate, fish or its decomposition product, defatted soybean cake or its decomposition product, etc. These nitrogen sources may be used alone or in combination of two or more, but are not limited thereto.
[0173] The above-mentioned components may include potassium phosphate monobasic, potassium phosphate dibasic, or their corresponding sodium-containing salts. Inorganic compounds may include sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. In addition, amino acids, vitamins, and / or suitable precursors may be included. These components or precursors may be added to the medium in batch or continuous manner, but are not limited thereto.
[0174] Additionally, during the cultivation of the microorganism of the present disclosure, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. may be added to the medium in an appropriate manner to adjust the pH of the medium. Furthermore, during the cultivation, foaming may be suppressed by using an antifoaming agent such as fatty acid polyglycol ester. Furthermore, to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas may be injected into the medium, or to maintain anaerobic and microaerobic states, nitrogen, hydrogen, or carbon dioxide gas may be injected without gas injection, but is not limited thereto.
[0175] In the culture of the present disclosure, the culture temperature can be maintained at 20 to 45°C, specifically 25 to 40°C, and the culture can be performed for about 10 to 160 hours, but is not limited thereto.
[0176] L-valine produced by the culture of the present disclosure may be secreted into the medium or remain within the cells.
[0177]
[0178] In one specific example, the method for producing L-valine of the present disclosure may further include, for example, prior to the culturing step, a step of preparing a microorganism of the present disclosure, a step of preparing a medium for culturing the strain, or a combination thereof (in any order).
[0179] In one specific example, the method for producing L-valine of the present disclosure may further comprise a step of recovering L-valine from the culture medium (the medium in which the culture is performed) or the microorganism of the present disclosure. The recovering step may be additionally included after the culturing step.
[0180] The above recovery may be performed by collecting L-valine using a suitable method known in the art according to the culture method of the microorganism of the present disclosure, such as a batch, continuous or fed-batch culture method. For example, various chromatographies such as centrifugation, filtration, treatment with a crystallizing protein precipitant (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, HPLC or a combination thereof may be used, and L-valine may be recovered from a medium or microorganism using a suitable method known in the art.
[0181] Additionally, the L-valine production method of the present disclosure may additionally include a purification step. The purification may be performed using any suitable method known in the art. In one example, when the L-valine production method of the present disclosure includes both a recovery step and a purification step, the recovery step and the purification step may be performed sequentially or discontinuously, regardless of order, or may be performed simultaneously or integrated into a single step, but is not limited thereto.
[0182] In the method of the present disclosure, the mutant polypeptide, polynucleotide, L-valine, etc. are as described in the other embodiments above.
[0183]
[0184] Another aspect of the present disclosure provides a composition for producing L-valine, comprising: a variant polypeptide of the present disclosure; a polynucleotide encoding the variant polypeptide; a vector comprising the polynucleotide; or a microorganism comprising the variant polypeptide of the present disclosure, a polynucleotide encoding the variant polypeptide, or a vector comprising the polynucleotide; a culture of the microorganism; or a combination of two or more thereof.
[0185] The composition of the present disclosure may further comprise any suitable excipient commonly used in compositions for producing L-valine, including but not limited to preservatives, wetting agents, dispersing agents, suspending agents, buffering agents, stabilizers, or isotonic agents.
[0186] In one specific example, each component present in the composition of the present disclosure may be included in a microbiologically effective amount, or an amount that can be suitably present in the composition for production.
[0187] In the composition of the present disclosure, the mutant polypeptide, polynucleotide, L-valine, etc. are as described in the other embodiments above.
[0188]
[0189] Another aspect of the present disclosure provides a use of a variant polypeptide of the present disclosure for producing L-valine.
[0190] The mutant polypeptide and L-valine of the present disclosure are as described in the other embodiments above.
[0191]
[0192] Another aspect of the present disclosure provides a use of a microorganism comprising a variant polypeptide of the present disclosure or a polynucleotide encoding the variant polypeptide for producing L-valine.
[0193] The mutant polypeptides, polynucleotides, L-valine, etc. of the present disclosure are as described in the other embodiments above.
[0194]
[0195] Another aspect of the present disclosure provides a method of increasing L-valine production capacity of a microorganism, comprising the step of modifying the microorganism to express a variant polypeptide of the present disclosure.
[0196] The mutant polypeptide, microorganism and L-valine of the present disclosure are as described in the other aspects above.
[0197] The above modification can be applied by various methods well known in the art, and includes, but is not limited to, a method of modifying a microorganism to express a variant of the present disclosure by transforming it with a vector containing a polynucleotide encoding the polynucleotide of the present disclosure or a variant of the present disclosure.
[0198]
[0199] The present disclosure is described in more detail below through examples. However, the following examples are merely preferred embodiments intended to illustrate the present disclosure and are therefore not intended to limit the scope of the present disclosure. Furthermore, technical details not described in this specification can be readily understood and implemented by those skilled in the technical field of the present disclosure or similar technical fields.
[0200]
[0201] Example 1. Selection of mutant strains with increased valine production through artificial mutation.
[0202]
[0203] Example 1-1. Induction of artificial mutations using gamma ray irradiation
[0204]
[0205] To select mutants with increased valine production, microbial mutations were induced using the following method.
[0206] Gamma irradiation, a physical method, was applied to induce mutations. High-energy gamma rays emitted from the source Co-60 flow along the chromosome, randomly triggering changes in the base sequence, such as base substitutions, deletions, and insertions. Since the level of base sequence change is proportional to the gamma irradiation intensity, high-level gamma rays induce mutations at a high rate while also increasing the killing rate of the strain. In order to sufficiently secure a high-quality, diverse mutant library with a high mutation rate, the gamma irradiation conditions for the Corynebacterial strains that were the target of gamma irradiation were first established. Using a high-level gamma irradiation device from Nordion, located at the Advanced Radiation Research Institute of the Korea Atomic Energy Research Institute, 30 mL of seed medium culture with an absorbance value of 6.09 at 562 nm was irradiated with gamma rays at intensities of 0, 0.5, 1, 2, 3, 4, 5, and 7.5 10 kGy / hr for 1 hour, and then 10 kGy / hr was added to the activated medium. 0 , 10 -1 , 10 -2 , 10 -3 , 10 -4 Each 100-㎕ of the gamma-irradiated solution was diluted at a dilution ratio of , and the plate medium on which the gamma-irradiated solution was spread was cultured in a 30°C static incubator for 48 hours. The number of individual colonies produced was counted to calculate the killing rate for each irradiation condition. The CFU / mL according to the gamma-irradiation conditions of 0, 0.5, 1, 2, 3, 4, 5, and 7.5 10-kGy / hr was 3.6 X 10 8 , 6.9X10 7 , 9.8X10 6 , 2.7X10 5 , 2.1X10 3 , 3.0X10 1, 0, 0, 0, and the killing rates were 0, 81.00467, 97.31540, 99.92589, 99.99942, 99.99999, 100, 100, 100%, respectively. It was confirmed that the gamma-ray irradiation condition for securing a high-quality mutant library with high mutation diversity through gamma-ray irradiation based on Corynebacteria strains was 4-kGy / hr based on the above irradiation conditions.
[0207] To obtain a microorganism with high L-valine production capacity, a mutant library based on gamma-irradiation was constructed targeting the KCCM11201P (US 8465962 B) strain, and L-valine high-production mutants were screened. For gamma-irradiation of the KCCM11201P strain, a 500-mL flask containing 50 mL of seed medium was cultured in a shaking incubator at 30°C for 24 h to obtain a culture with an absorbance value of 7.84 at 562 nm, which was then diluted using the seed medium to obtain an absorbance value of 6.10 at 562 nm. Using a high-level gamma irradiation device at the Advanced Radiation Research Institute of the Korea Atomic Energy Research Institute, 30 mL of the diluted solution was irradiated with 4 kGy / hr of gamma rays for 1 hour, and then 100 μL of the irradiation solution was spread on each of 100 90 X 15 mm Petri dishes in activation medium. The Petri dishes were cultured in a 30°C stationary incubator for 48 hours, and a total of approximately 40,000 individual colonies were obtained. To ensure mutant stability, all individual colonies formed in all Petri dishes were collected, suspended in a 20% glycerol solution, and then aliquoted into 1.5 mL microtubes of 1 mL each and stored in an ultra-low temperature freezer at -80°C.
[0208]
[0209] Example 1-2. Evaluation of fermentation activity of mutant strains and strain selection
[0210]
[0211] In order to select mutants with increased L-valine production ability compared to Corynebacterium glutamicum KCCM11201P used as a parent strain, fermentation titer tests were performed on strains in which random mutations were induced. When screening for mutants with high L-valine production ability, a 20% glycerol suspension taken out of an ultra-low temperature freezer and thawed at room temperature was diluted with saline for 10 -1 , 10 -2 , 10 -3 , 10 -4 , 10 -5 After serial dilution, 100 μl of the diluted solution corresponding to each dilution factor was spread on the activation medium, and individual colonies were reactivated through 24 h of culture in a 30°C stationary incubator. The reactivated individual colonies were inoculated into a 96-Deep Well Plate, which had 350 μl of the production medium dispensed per well at a filling rate of 17%, using a Qpix420 Colony Picker facility from Molecular Devices. In the same plate, the KCCM11201P strain that had not been irradiated with gamma rays was inoculated into four wells per plate to serve as a control for screening high-L-valine producing mutants. The 96-Deep Well Plate, each inoculated with the control strain and the mutants, was sealed using a Gas permeable seal mark2 from Azenta and cultured in a Multitron shaking incubator from Infors-HT at 30°C and 1,000 rpm for 48 h. The 96 Deep Well Plate cultured for 48 hours was centrifuged for 20 minutes at 15°C and 4,000 rpm in an Eppendorf Centrifuge 5810R. The culture supernatant from which the cells were separated was transferred to a Corning 96 Well Black Polystyrene Microplate using a Beckman Coulter Liquid Handler, Biomek i5, for NIR Spectrometry analysis. Afterwards, individual analysis spectra of each well were obtained using NIR Spectrometry, and 16 strains with excellent L-valine concentrations were initially selected among 10,304 mutant strains. Afterwards, the 16 selected strains were cultured in the same manner as above and the concentration of L-valine was analyzed.
[0212]
[0213] [Nutrient medium (pH 7.2)]
[0214] 10g glucose, 5g meat extract, 10g polypeptone, 2.5g sodium chloride, 5g yeast extract, 20g agar, 2g urea (per 1 liter of distilled water)
[0215]
[0216] [Production medium (pH 7.0)]
[0217] Glucose 100 g, ammonium sulfate 40 g, soy protein 2.5 g, corn steep solids 5 g, urea 3 g, potassium phosphate dibasic 1 g, magnesium sulfate heptahydrate 0.5 g, biotin 100 μg, thiamine-HCl 1 mg, calcium pantothenate 2 mg, nicotinamide 3 mg, calcium carbonate 30 g (based on 1 liter of distilled water)
[0218] As a result, the C7 strain (valine production: 4.2 g / L) was selected, which had a 2-fold increase in valine production compared to the parent strain KCCM11201P (valine production: 2.1 g / L).
[0219]
[0220] Example 2. Mutation identification through gene sequencing
[0221]
[0222] The main genes of the above strain were sequenced and compared with the KCCM11201P strain. As a result, it was confirmed that the strain with increased valine production ability contains a base sequence mutation at a specific location in the ORF (open reading frame) region of the ilvN gene. Specifically, the C7 strain contains the same A42V mutation as the parent strain KCCM11201P, and in addition, it was confirmed that one mutation was introduced at a base located 461 bp upstream from the start codon of the ilvN gene, changing the existing CAA (SEQ ID NO: 2) to CGA (SEQ ID NO: 4), and the 154th amino acid glutamine was substituted with arginine (SEQ ID NO: 3).
[0223] In the following examples, it was attempted to determine whether the Q154R mutation inserted into a specific ORF position within the ilvN gene affects the production ability of valine, a branched-chain amino acid, in microorganisms of the genus Corynebacterium.
[0224]
[0225] Example 3-1. Production of a strain with an IlvN mutation introduced into Corynebacterium glutamicum KCCM11201P strain and evaluation of L-valine production ability.
[0226]
[0227] To insert the IlvN (Q154R) mutant into Corynebacterium glutamicum KCCM11201P containing the A42V mutation, a vector containing the target mutation was constructed. Specifically, the genomic DNA of the C7 strain was extracted using a G-spin Total DNA Extraction Mini Kit (Intron, Cat. No. 17045) according to the protocol provided in the kit, and PCR was performed using the genomic DNA as a template. The PCR conditions were as follows: denaturation at 94°C for 5 minutes; 25 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 150 seconds; and polymerization was performed at 72°C for 7 minutes. A 951 bp PCR product (hereinafter referred to as “mutation introduction fragment 1”) was obtained using SEQ ID NOs: 11 and 12.
[0228] The above-obtained mutant fragment 1 was ligated to the pDC24 vector (SEQ ID NO: 29) treated with the restriction enzyme SmaI (New England Biolabs, Beverly, MA) using an Infusion Cloning Kit (Takara Bio Inc., Otsu, Japan), and then transformed into Escherichia coli DH5α. After transforming the constructed gene into E. coli DH5α, the resulting strain was selected on LB medium containing kanamycin, and DNA was obtained using a DNA-spin plasmid DNA purification kit (iNtRON) to prepare vector pDC24-ilvN (Q154R) containing the above-obtained mutant fragment 1.
[0229]
[0230] Primer base sequence SEQ ID NO: 11CCCGGG ATGGCTAATTCTGACGTCA SEQ ID NO: 12CCCGGG TGTCTGGAGCCAGGAGCAT
[0231] The above pDC24-ilvN(Q154R) was transformed into Corynebacterium glutamicum KCCM11201P by homologous recombination on the chromosome (van der Rest et al., Appl Microbiol Biotechnol 52:541-545, 1999). Strains in which the vector was inserted into the chromosome by recombination of homologous sequences were selected on a medium containing 25 mg / L of kanamycin. After completing the second recombination, the above-mentioned Corynebacterium glutamicum transformant was subjected to PCR using SEQ ID NO: 11 and SEQ ID NO: 12 to confirm that it contained the same A42V mutation as the parent strain KCCM11201P, in which alanine was substituted with valine at amino acid position 42 of SEQ ID NO: 1 in the ORF of the ilvN gene on the chromosome, and in addition, a strain in which glutamine was substituted with arginine at amino acid position 154 of SEQ ID NO: 1 in the ORF of the ilvN gene was confirmed. The recombinant strain was named Corynebacterium glutamicum KCCM11201P::ilvN(Q154R).
[0232] To compare the valine production capacity of Corynebacterium glutamicum KCCM11201P and KCCM11201P::ilvN(Q154R), valine-producing strains, a flask assay was performed. Each strain was subcultured in nutrient medium, and then inoculated into a 250-mL corner-baffle flask containing 25 mL of production medium, followed by shaking culture at 30°C for 72 hours at 200 rpm. The concentration of L-valine was then analyzed using HPLC, and the analyzed L-valine concentrations are shown in Table 2 below.
[0233]
[0234] [Nutrient medium (pH 7.2)]
[0235] 10g glucose, 5g meat extract, 10g polypeptone, 2.5g sodium chloride, 5g yeast extract, 20g agar, 2g urea (per 1 liter of distilled water)
[0236]
[0237] [Production medium (pH 7.0)]
[0238] Glucose 100 g, ammonium sulfate 40 g, soy protein 2.5 g, corn steep solids 5 g, urea 3 g, potassium phosphate dibasic 1 g, magnesium sulfate heptahydrate 0.5 g, biotin 100 μg, thiamine-HCl 1 mg, calcium pantothenate 2 mg, nicotinamide 3 mg, calcium carbonate 30 g (based on 1 liter of distilled water)
[0239]
[0240] KCCM11201P and KCCM11201P::ilvN(Q154R) L-valine producing strains L-valine (g / L) Batch 1 Batch 2 Batch 3 Average KCCM11201P 2.7 2.9 2.7 2.7 KCCM11201P::ilvN(Q154R) 3.3 3.2 3.4 3.3
[0241] As a result, it was confirmed that the L-valine production ability of the KCCM11201P::ilvN(Q154R) strain increased by 22% compared to KCCM11201P.
[0242] Example 3-2. Production of a strain with an IlvN mutation introduced into Corynebacterium glutamicum KCCM11201P strain and evaluation of L-valine production ability - 2
[0243]
[0244] To confirm the effect of only the IlvN (Q154R) mutation in the wild-type IlvN enzyme, a strain was created in which glutamine at amino acid position 154 of sequence number 1 in the ORF of the ilvN gene in KCCM11201P was substituted with wild-type arginine.
[0245] Specifically, the above pDC24-ilvN(Q154R) was transformed into Corynebacterium glutamicum KCCM11201P by homologous recombination on the chromosome (van der Rest et al., Appl Microbiol Biotechnol 52:541-545, 1999). The strain in which the vector was inserted on the chromosome by recombination of homologous sequences was selected on a medium containing 25 mg / L of kanamycin. After the secondary recombination was completed, the above-mentioned Corynebacterium glutamicum transformant was subjected to PCR using SEQ ID NO: 11 and SEQ ID NO: 12. The mutation contained in the parent strain KCCM11201P, in which alanine was substituted with valine at amino acid position 42 of SEQ ID NO: 1 in the ORF of the ilvN gene on the chromosome, was restored to alanine, and a strain was confirmed in which glutamine was substituted with arginine at amino acid position 154 of SEQ ID NO: 1 in the ORF of the ilvN gene. The recombinant strain was named Corynebacterium glutamicum KCCM11201P::ilvN (V42A, Q154R). In addition, in order to exclude the restoration effect of the A42V mutation in the ilvN gene in the KCCM11201P strain and confirm only the effect of Q154R, the KCCM11201P::ilvN(V42A) strain, in which only the A42V mutation was restored in the same manner, was also selected as a control.
[0246] Subsequently, flask evaluation was performed to compare the valine production ability of KCCM11201P::ilvN(V42A) and KCCM11201P::ilvN(V42A, Q154R). After subculturing each strain in nutrient medium, each strain was inoculated into a 250-mL corner-baffle flask containing 25 mL of production medium, and cultured at 30°C for 72 hours with shaking at 200 rpm. Thereafter, the concentration of L-valine was analyzed using HPLC, and the analyzed L-valine concentrations are shown in Table 3 below.
[0247]
[0248] KCCM11201P::ilvN(V42A) and KCCM11201P::ilvN(V42A,Q154R) L-valine producing strains L-valine (g / L) Batch 1 Batch 2 Batch 3 Average KCCM11201P::ilvN(V42A) 2.2 2.1 2.2 2.2 KCCM11201P::ilvN(V42A, Q154R) 2.7 2.6 2.7 2.7
[0249] As a result, it was confirmed that the L-valine production ability of the KCCM11201P::ilvN(V42A, Q154R) strain increased by 23% compared to KCCM11201P::ilvN(V42A).
[0250]
[0251] Example 4: Production of a strain with an IlvN mutation introduced into Corynebacterium glutamicum CJ7V strain and evaluation of L-valine production ability.
[0252]
[0253] In order to determine whether the effect of increasing L-valine production was also present in other strains of Corynebacterium glutamicum that produce L-valine, a strain with improved L-valine production was created by introducing a mutation [ilvN(A42V); Biotechnology and Bioprocess Engineering, June 2014, Volume 19, Issue 3, pp 456-467] into the wild strain Corynebacterium glutamicum ATCC14067.
[0254] Specifically, genomic DNA of Corynebacterium glutamicum wild type ATCC14067 strain was extracted using a G-spin Total DNA Extraction Mini Kit (Intron, Cat. No. 17045) according to the protocol provided in the kit. PCR was performed using the genomic DNA as a template. To construct a vector introducing the A42V mutation into the ilvN gene, gene fragments (A, B) were obtained using primer pairs of SEQ ID NOs: 13 and 14 and primer pairs of SEQ ID NOs: 15 and 16, respectively. PCR conditions were as follows: denaturation at 94°C for 5 minutes; 25 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 60 seconds; and polymerization at 72°C for 7 minutes.
[0255] As a result, polynucleotides of 528 bp and 509 bp, respectively, were obtained for fragments A and B. Overlapping PCR was performed using the above two fragments as templates and sequence numbers 12 and 15, respectively, to obtain a 1010 bp PCR product (hereinafter referred to as "mutation-introduced fragment 2").
[0256] The above-obtained mutant fragment 2 was treated with the restriction enzyme SmaI (New England Biolabs, Beverly, MA), and then ligated with the pDC24 vector treated with the same restriction enzyme using T4 ligase (New England Biolabs, Beverly, MA). The constructed gene was transformed into E. coli DH5α, which was then selected on LB medium containing kanamycin, and DNA was obtained using a DNA-spin plasmid DNA purification kit (iNtRON). The vector for the purpose of introducing the A42V mutation of the ilvN gene was named pDC24-ilvN(A42V).
[0257]
[0258] Primer base sequences SEQ ID NO: 13cggggatcccccgggAGGACGGTACTCAAATACTAAACTTCSEQ ID NO: 14TGCCGAGTGTTTCGGTCTTTACAGACACGAGGGACACGSEQ ID NO: 15TGTCTGTAAAGACCGAAACACTCGGCATCAASEQ ID NO: 16cggggatcccccgggGACAACTACATTATTATTATACCACA
[0259] Thereafter, the pDC24-ilvN(A42V) was transformed into the wild-type Corynebacterium glutamicum ATCC14067 by homologous recombination on the chromosome (van der Rest et al., Appl Microbiol Biotechnol 52:541-545, 1999). The strain in which the vector was inserted into the chromosome by recombination of the homologous sequence was selected on a medium containing 25 mg / L of kanamycin. After that, the gene fragment was amplified by PCR using SEQ ID NO: 13 and SEQ ID NO: 16 for the above Corynebacterium glutamicum transformant that completed the second recombination, and the mutant insertion strain was confirmed through gene sequence analysis. The recombinant strain was named Corynebacterium glutamicum CJ7V.
[0260] Finally, a strain was constructed by transforming the above-mentioned Corynebacterium glutamicum CJ7V with a vector in the same manner as in Example 3, and was named Corynebacterium glutamicum CJ7V::ilvN(Q154R). In order to compare the L-valine production ability of the constructed strain, it was cultured in the same manner as in Example 3, and the concentration of L-valine was analyzed. The analyzed concentration of L-valine is shown in Table 5 below.
[0261]
[0262] CJ7V, CJ7V::ilvN ( L-valine production ability strain of Q154R) L-valine (g / L) Batch 1 Batch 2 Batch 3 Average CJ7V 2.2 2.1 2.2 2.2 CJ7V::ilvN (Q154R) 2.8 2.7 2.7 2.7
[0263] As a result, it was confirmed that the L-valine production ability of the CJ7V::ilvN(Q154R) strain increased by 23% compared to CJ7V.
[0264] Example 5: Production of a strain with an IlvN mutation introduced into Corynebacterium glutamicum CJ8V strain and evaluation of L-valine production ability.
[0265]
[0266] To determine whether the effect of increasing L-valine production was also observed in other strains of Corynebacterium glutamicum that produce L-valine, a strain with improved L-valine production was produced by introducing a mutation [ilvN(A42V); Biotechnology and Bioprocess Engineering, June 2014, Volume 19, Issue 3, pp 456-467] into Corynebacterium glutamicum ATCC13869 (KR 10-1947945 B1).
[0267] Specifically, in Example 4, the constructed vector pDC24-ilvN (A42V) was transformed into the wild-type Corynebacterium glutamicum ATCC13869 strain to induce homologous recombination on the chromosome (van der Rest et al., Appl Microbiol Biotechnol 52:541-545, 1999). The strain in which the vector was inserted into the chromosome by recombination of the homologous sequence was selected on a medium containing 25 mg / L of kanamycin. The selected Corynebacterium glutamicum transformant was subjected to PCR using a primer pair of SEQ ID NOs: 17 and 18 to amplify a gene fragment, and gene sequence analysis confirmed that the mutation had been properly introduced. The recombinant strain was named Corynebacterium glutamicum CJ8V. The sequences of the primers used in this example are shown in Table 6 below.
[0268]
[0269] Primer base sequence SEQ ID NO: 17CCGCGTCACCAAAGCGGA SEQ ID NO: 18TTAGATCTTGGCCGGAGCCA
[0270] Finally, a strain was constructed by transforming the above-mentioned Corynebacterium glutamicum CJ8V with a vector in the same manner as in Example 3, and was named Corynebacterium glutamicum CJ8V::ilvN(Q154R). In order to compare the L-valine production ability of the constructed strain, it was cultured in the same manner as in Example 3, and the concentration of L-valine was analyzed, and the analyzed concentration of L-valine is shown in Table 7 below.
[0271]
[0272] L-valine production ability of CJ8V, CJ8V::ilvN(Q154R) strain L-valine (g / L) Batch 1 Batch 2 Batch 3 Average CJ8V 1.9 1.8 1.9 1.9 CJ8V::ilvN(Q154R) 2.1 2.2 2.2 2.2
[0273] As a result, it was confirmed that the L-valine production ability of the CJ8V::ilvN(Q154R) strain increased by 16% compared to CJ8V.
[0274]
[0275] Example 6. Production of KCCM11201P strain with Q154X mutation and confirmation of valine production ability.
[0276]
[0277] To confirm the effect of the 154th mutation position of IlvN, site-directed mutagenesis was performed using pDC24-ilvN (Q154R) used in Example 3-1 as a template to mutate the 154th amino acid, glutamine, to an amino acid other than arginine. Site-directed mutagenesis was performed using the following method.
[0278]
[0279] Site-Direction Mutagenesis PCR composition unit (ul)10X pfu-
[0280] Site-Direction Mutagenesis PCR cycleCycleTemperatureTime195 ℃1 min1895 ℃50 sec60 ℃50 sec68 ℃9 min168 ℃7 min
[0281] In order to substitute glutamine, the 154th amino acid of IlvN, with histidine (H) or glutamic acid (E), which are amino acids other than arginine, each mutagenic primer set shown in Table 10 below was used to create a PCR mixture as shown in Table 8, and PCR was performed with the cycles shown in Table 9 above. After PCR was completed, the pDC24_ilvN mutant plasmid was transformed into E. coli DH5α using an Infusion Cloning Kit (Takara Bio Inc., Otsu, Japan), and it was confirmed through sequencing that it had been replaced with each mutation shown in Table 10 below.
[0282]
[0283] Mutagenic primer set for constructing a plasmid with a 154th amino acid mutation in the IlvN amino acid sequence. Mutant ilvN plasmid sequence number (5'-3') pDC24_ilvN (Q154H) 19CGAACTGATCcacTCCGGACAGA 20TCTGTCCGGAgtgGATCAGTTCG pDC24_ilvN (Q154E) 21CGAACTGATCgagTCCGGACAGA 22TCTGTCCGGActcGATCAGTTCG
[0284] As shown in Table 10 above, the pDC24_ilvN (Q154H) and pDC24_ilvN (Q154E) vectors were constructed and transformed into KCCM11201P by electroporation, and two strains with the mutant ilvN gene inserted into the chromosome were obtained through a second crossing process. The genetic manipulation was confirmed through PCR using primers of SEQ ID NOs: 11 and 12 that can amplify the external regions of the upstream and downstream regions of the homologous recombination region where the gene was inserted, and genome sequencing.
[0285] The transformed strains thus obtained were named KCCM11201P::ilvN(Q154H) and KCCM11201P::ilvN(Q154E), respectively.
[0286] The two strains created in Example 6 were cultured in the same manner as in Example 3 to compare the valine production ability with the KCCM11201P::ilvN (Q154R) strain created in Example 3, and the concentration of L-valine was analyzed. The analyzed concentration of L-valine is shown in Table 11 below.
[0287]
[0288] L-valine production ability of strains with a mutant replacement of amino acid 154 of the IlvN amino acid sequence. Strain name L-valine (g / L). Control group KCCM11201P2.7. Experimental group KCCM11201P::ilvN(Q154R)3.3 KCCM11201P::ilvN(Q154H)3.2 KCCM11201P::ilvN(Q154E)3.3
[0289] As a result, it was confirmed that the L-valine production ability of the KCCM11201P::ilvN(Q154R) strain increased by 22% compared to KCCM11201P, the L-valine production ability of the KCCM11201P::ilvN(Q154H) strain increased by 19% compared to KCCM11201P, and the L-valine production ability of the KCCM11201P::ilvN(Q154E) strain increased by 22% compared to KCCM11201P.
[0290]
[0291] From the above description, those skilled in the art will understand that the present disclosure can be implemented in other specific forms without altering its technical spirit or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present disclosure should be interpreted as encompassing all changes or modifications derived from the meaning and scope of the following claims and their equivalent concepts, rather than the detailed description above.
Claims
1. A mutant polypeptide in which the amino acid corresponding to position 154 of sequence number 1 is replaced with another amino acid.
2. A mutant polypeptide in the first paragraph, wherein the amino acid corresponding to the 154th position of the sequence number 1 is substituted with an amino acid containing a charged side chain (electrically charged amino acid).
3. A mutant polypeptide according to claim 2, wherein the amino acid containing the charged side chain is arginine, histidine or glutamic acid.
4. In the first paragraph, the mutant polypeptide comprises any one of the amino acid sequences represented by the following general formulas 1 to 3: [General Formula 1] EPFGIRELIX [General Formula 2] PGKLRALLDVLEPFGIRELIX [General Formula 3] GINRITVVVDADELNIEQITKQLNKLIPVLKVVRLDEETTIARAIMLVKVSADSTNRPQIVDAANIFRARVVDVAPDSVVIESTGTPGKLRALLDVMEPFGIRELIX In the above general formulas 1 to 3, X is an amino acid containing a charged side chain.
5. A mutant polypeptide according to claim 4, wherein X is arginine, histidine or glutamic acid.
6. In the first paragraph, the mutant polypeptide is a mutant polypeptide in which the amino acid corresponding to the 42nd position in the amino acid sequence of SEQ ID NO: 1 is additionally replaced with a different amino acid.
7. A mutant polypeptide according to claim 6, wherein the other amino acid is valine.
8. In the sixth paragraph, the variant polypeptide comprises the amino acid sequence NLVSLVSV, LSVLVQDVDGIISRVSGMFTRRAFNLVSLVSV, or MANSDVTRHILSVLVQDVDGIISRVSGMFTRRAFNLVSLVSV.
9. In the first paragraph, the mutant polypeptide comprises an amino acid sequence having at least 70% identity and less than 100% identity with the sequence number 1.
10. A variant polypeptide according to claim 1, wherein the variant polypeptide is a variant of an acetohydroxy acid synthase subunit.
11. A variant polypeptide according to claim 1, wherein the variant polypeptide comprises an amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO:
10.
12. A polynucleotide encoding a mutant polypeptide of any one of claims 1 to 11.
13. A microorganism comprising a variant polypeptide of any one of claims 1 to 11 or a polynucleotide encoding the variant polypeptide.
14. In claim 13, the microorganism has increased L-valine production ability compared to a microorganism containing the polypeptide of sequence number 1 or a polynucleotide encoding the same.
15. A microorganism according to claim 13, wherein the microorganism is a microorganism of the genus Corynebacterium.
16. A microorganism according to claim 15, wherein the microorganism of the genus Corynebacterium is Corynebacterium glutamicum.
17. A method for producing L-valine, comprising a step of culturing the microorganism of claim 13 in a medium.
18. A method for producing L-valine, further comprising a step of recovering L-valine from the cultured microorganism, a culture of the microorganism, a fermented product of the microorganism, or the culture medium in accordance with paragraph 17.
19. A composition for producing L-valine, comprising a variant polypeptide of any one of claims 1 to 11; a polynucleotide encoding the variant polypeptide; a microorganism comprising the variant polypeptide or a polynucleotide encoding the variant polypeptide; a culture of the microorganism; or a combination of two or more thereof.
20. Use of a variant polypeptide according to any one of claims 1 to 11; or a microorganism comprising the variant polypeptide or a polynucleotide encoding the variant polypeptide; for producing L-valine.
21. A method for increasing the L-valine production ability of a microorganism, comprising the step of modifying the microorganism to express a mutant polypeptide of any one of claims 1 to 11.
Citation Information
Patent Citations
Corynebacterium glutamicum) CH45(NOVEL CORYNEBACTERIUM GLUTAMICUM CH45 WHICH PRODUCE L-LEUCINE
KR100220018B1
L-leucine producing microorganism corynebacterium glutamicum ch25 having tolerance against norleucine, alpha-aminobutyric acid and l-arginine hydroxamate
KR100438146B1
A microorganism of the genus Corynebacterium producing L-amino acids and method for producing L-amino acids using the same
KR101947945B1
Microorganism of the genus Corynebacterium producing L-amino acids and a method for producing L-amino acids using the same
US11180784B2
Microorganism having enhanced L-valine productivity and method for producing L-valine using the same
US8465962B2
Cited By
Protein variant and method for producing L-isoleucine using same
CN121941700A
Protein variants and methods of producing l-isoleucine using the same
CN122940868A
Protein variants and methods of producing l-isoleucine using the same
CN122941630A
Protein variants and methods for producing L-isoleucine using them
CN123062545A
Variant of protein and method for producing l-isoleucine by using same
WO2025244356A1
